Atjaunināt sīkdatņu piekrišanu

Clinical Handbook of Psychotropic Drugs 19th, revised and expanded ed [Spiral bound]

4.33/5 (18 ratings by Goodreads)
  • Formāts: Spiral bound, 362 pages, height x width: 280x216 mm, full colour, with pdf patient handouts
  • Izdošanas datums: 29-Sep-2011
  • Izdevniecība: Hogrefe Publishing
  • ISBN-10: 0889373957
  • ISBN-13: 9780889373952
Citas grāmatas par šo tēmu:
  • Spiral bound
  • Cena: 72,05 €*
  • * Šī grāmata vairs netiek publicēta. Jums tiks paziņota lietotas grāmatas cena
  • Šī grāmata vairs netiek publicēta. Jums tiks paziņota lietotas grāmatas cena.
  • Daudzums:
  • Ielikt grozā
  • Pievienot vēlmju sarakstam
  • Formāts: Spiral bound, 362 pages, height x width: 280x216 mm, full colour, with pdf patient handouts
  • Izdošanas datums: 29-Sep-2011
  • Izdevniecība: Hogrefe Publishing
  • ISBN-10: 0889373957
  • ISBN-13: 9780889373952
Citas grāmatas par šo tēmu:
The Clinical Handbook of Psychotropic Drugs has become a standard reference and practical tool for psychiatrists, psychiatric nurses, pharmacists, psychologists, physicians, and all mental health professionals. The new and fully updated 19th edition retains all the practical features for which the Clinical Handbook is renowned: - Independent, unbiased - Packed with unique comparison charts (dosages, side effects, pharmacokinetics, interactions - ) that allow you to see at a glance which medication is the most suitable for each patient - Instantly recognizable icons and full color throughout, allowing you to find at a glance all the information you seek - The latest information on newly released drugs, adverse effects, approved indications (see below for details) - Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more - all you need to know for each class of drug - Patient Handouts, Herbal and NaturalA" Products, Unapproved Treatments, ECT, BLT, rTMS New in this edition: - Pharmacotherapy for nicotine/tobacco use - Extensive revisions and additions to the antipsychotics, including dosing, adverse effects, interactions, precautions - New dosage/pharmacokinetics comparison chart for extrapyramidal agents - Extensive revisions to benzodiazepines and hypnotics/sedatives comparison chart - Updates on unapproved treatments (e.g. , pregabalin and vigabatrin for alcohol and cocaine dependence) and herbal and naturalA" products (e.g., for treatment of depression) - Hundreds of new references - Printable (PDF) patient handouts - Drugs with recent/changed approval include: iloperidone (Fanapt), asenapine sublingual (Saphris), guanfacine (Tenex, Intuniv), degarelix (Firmagon), finasteride (Proscar) - Preparations added include: Symbyax, Prozac Weekly, Luvox CR, Aplenzin, Oleptro, Silenor, Zonolon, Invega Sustenna, Zyprexa Relprevv, Mellaril, Compoz, Epitol, Teril, Compoz, Nytol, Simply Sleep, Sominex, Unisom, clonidine SR (Kapvay)
Antidepressants
2(70)
Selective Serotonin Reuptake Inhibitors (SSRI)
3(12)
Norepinephrine Dopamine Reuptake Inhibitor (NDRI)
15(5)
Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
20(5)
Serotonin-2 Antagonists/Reuptake Inhibitors (SARI)
25(6)
Noradrenergic/Specific Serotonergic Antidepressants (NaSSA)
31(4)
Vilazodone
35(2)
Nonselective Cyclic Antidepressants
37(8)
Monoamine Oxidase Inhibitors
45(1)
Reversible Inhibitor of MAO-A (RIMA)
45(3)
Irreversible Monoamine Oxidase Inhibitors
48(6)
Monoamine Oxidase B Inhibitor
54(3)
Effects of Antidepressants on Neurotransmitters/Receptors
57(1)
Pharmacological Effects of Antidepressants on Neurotransmitters/Receptors
58(1)
Frequency of Adverse Reactions to Antidepressants at Therapeutic Doses
59(3)
Antidepressant Doses and Pharmacokinetics
62(3)
Switching Antidepressants
65(2)
Antidepressant Augmentation Strategies
67(5)
Electroconvulsive Therapy (ECT)
72(6)
Bright Light Therapy (BLT)
78(2)
"Repetitive Transcranial Magnetic Stimulation (rTMS)
80(4)
Antipsychotics
84(90)
"Second-Generation" Antipsychotics/SGAs
90(29)
"Third-Generation" Antipsychotic/TGA
119(7)
"First-Generation" Antipsychotics/FGAs
126(18)
Effects of Antipsychotics on Neurotransmitters/Receptors
144(1)
Pharmacological Effects of Antipsychotics on Neurotransmitters/Receptors
145(1)
Frequency (%) of Adverse Reactions to Antipsychotics at Therapeutic Doses
146(2)
Antipsychotic Doses and Pharmacokinetics (Oral and Short-Acting Injections)
148(10)
Comparison of Long-Acting IM Antipsychotics
158(4)
Extrapyramidal Adverse Effects of Antipsychotics
162(3)
Switching Antipsychotics
165(2)
Antipsychotic Augmentation Strategies
167(7)
Agents for Treating Extrapyramidal Side Effects
174(10)
Effects on Extrapyramidal Symptoms
178(1)
Comparison of Agents for Treating Extrapyramidal Side Effects
179(2)
Doses and Pharmacokinetics of Agents for Treating Extrapyramidal Side Effects
181(3)
Anxiolytic (Antianxiety) Agents
184(17)
Benzodiazepines
184(8)
Comparison of the Benzodiazepines
192(4)
Buspirone
196(5)
Hypnotics/Sedatives
201(13)
L-Tryptophan
206(3)
Comparison of Hypnotics/Sedatives
209(5)
Mood Stabilizers
214(30)
Lithium
214(8)
Anticonvulsants
222(14)
Comparison of Anticonvulsants
236(6)
Frequency of Adverse Reactions to Mood Stabilizers at Therapeutic Doses
242(2)
Drugs for ADHD
244(20)
Psychostimulants
244(8)
Atomoxetine
252(3)
Comparison of Drugs for ADHD
255(4)
α2 agonists
259(3)
Augmentation Strategies in ADHD
262(2)
Drugs for Treatment of Dementia
264(12)
Cholinesterase Inhibitors
264(5)
Memantine
269(2)
Comparison of Drugs for Treatment of Dementia
271(5)
Sex-Drive Depressants
276(4)
Comparison of Sex-Drive Depressants
278(2)
Drugs of Abuse
280(29)
Alcohol
282(5)
Stimulants
287(4)
Hallucinogens
291(7)
Opiates/Narcotics
298(3)
Inhalants/Aerosols
301(2)
Gamma-hydroxybutyrate (GHB)/Sodium Oxybate
303(2)
Flunitrazepam (Rohypnol)
305(1)
Nicotine/Tobacco
306(3)
Treatment of Substance Use Disorders
309(21)
Disulfiram
309(3)
Acamprosate
312(2)
Naltrexone
314(3)
Methadone
317(4)
Buprenorphine
321(3)
Pharmacotherapy for Nicotine/Tobacco Use Dependence
324(6)
Unapproved Treatments of Psychiatric Disorders
330(9)
Adrenergic Agents
330(2)
Dopaminergic Agents
332(2)
GABA-Agents/Anticonvulsants
334(2)
Hormones
336(1)
Miscellaneous
337(2)
Herbal and "Natural" Products
339(8)
Glossary 347(4)
Suggested Resources for Information Regarding Drug Use in Pregnancy and Effects on Breast Milk 351(1)
Patient Information Sheets 352(1)
Index of Drugs 353